Skip to main content
Premium Trial:

Request an Annual Quote

Cetek and Tularik Collaborate on Assays, Screening

NEW YORK, Feb. 6--Cetek Corporation will collaborate with Tularik in a project to develop assays and discover lead compounds, the company said today.


The partnership will apply Cetek's CE Assay, a capillary electrophoresis system to rank small molecule affinity for therapeutic target proteins, to develop lead compounds.


The companies did not reveal financial details nor discuss the therapeutic area for this collaboration.


Tularik is a publicly owned drug development company with research programs in cancer, viral disease, immune disorders, inflammation, obesity, diabetes and lipid disorders.


Cetek, based in Marlborough, Mass., is privately held. Its CE Assay system is the basis of a range collaborations with pharmaceutical and biotech firms.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.